IRVINE, Calif., Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced U.S. Food and Drug ...

(RTTNews) - Edwards Lifesciences (EW) said it received approval from the U.S. Food and Drug Administration for the use of the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive prestent ...

The FDA approved a new version of Edwards Lifesciences’ Sapien 3 transcatheter heart valve—coupling it with a self-expanding, stent-like device that helps reshape a malfunctioning pulmonary valve.

The FDA gave the greenlight to transcatheter pulmonic valve replacement with the Sapien 3 system plus an adaptive pre-stent landing zone, dubbed Alterra, for patients with congenital heart disease.

Please provide your email address to receive an email when new articles are posted on . Edwards Lifesciences Corporation announced that its transcatheter heart valve has received FDA approval for ...

The Edwards SAPIEN 3 Transcatheter Pulmonary Valve (“TPV”) system with Alterra adaptive prestent is indicated for use in the management of pediatric and adult patients with extreme pulmonary ...

The US Food and Drug Administration (FDA) has cleared Edwards Lifesciences’ SAPIEN 3 transcatheter valve with the Alterra adaptive prestent for pulmonic heart valve replacement, the manufacturer ...

The US Food and Drug Administration (FDA) has approved use of the Edwards SAPIEN 3 transcatheter valve with the Alterra adaptive prestent (Sapien 3 with Alterra) for patients with severe pulmonary ...

Edwards Lifesciences Corp. appears to be milking as many indications as possible from its transcatheter heart valve (THV) platform. The FDA just approved the company's Sapien XT valve for pulmonic ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: The ALTERRA Post-Approval ...